Payment overview · 2025
General Payments
$743.20
48 reported records · 12 companies
Healthcare provider profile · identity verified
Deidre Brown, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ENGLEWOOD, TN · NPI 1588110365
Verified facts
What the public records show
CMS Open Payments records show Deidre Brown, FNP-C received $743.20 in general payments during 2025 across 48 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 40.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Aristada, Mounjaro, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Vraylar by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Aristada by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $297.04 | 40.0% | 23 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $136.40 | 18.4% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $78.76 | 10.6% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $64.15 | 8.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.33 | 4.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $29.14 | 3.9% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.93 | 2.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.36 | 2.6% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $17.48 | 2.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.14 | 2.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.91 | 2.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.56 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $743.20 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $297.04 | 23 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $136.40 | 8 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $81.28 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $78.76 | 4 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $64.15 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $62.47 | 4 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.91 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ARISTADA aristada |
2025 | Aristada | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 96 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
47 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
96 | 13 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 1492 | 150 |
| Gabapentin | Gabapentin | 552 | 69 |
| Omeprazole | Omeprazole | 500 | 79 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 464 | 88 |
| Lisinopril | Lisinopril | 396 | 63 |
| Levothyroxine Sodium | Levothyroxine Sodium | 319 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 260 | 44 |
| Atorvastatin Calcium | Atorvastatin Calcium | 231 | 48 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 201 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 189 | 32 |
| Metformin Hcl | Metformin Hcl | 179 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 174 | 19 |
| Prednisone | Prednisone | 167 | 85 |
| Pregabalin | Pregabalin | 167 | 19 |
| Promethazine Hcl | Promethazine Hcl | 165 | 33 |
| Simvastatin | Simvastatin | 165 | 25 |
| Azithromycin | Azithromycin | 153 | 89 |
| Ibuprofen | Ibuprofen | 146 | 30 |
| Montelukast Sodium | Montelukast Sodium | 145 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 142 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 141 | 24 |
| Mirtazapine | Mirtazapine | 134 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 133 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 131 | 27 |
| Clonazepam | Clonazepam | 130 | 16 |
| Tramadol Hcl | Tramadol Hcl | 130 | 17 |
| Meloxicam | Meloxicam | 129 | 33 |
| Potassium Chloride | Potassium Chloride | 125 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 124 | 20 |
| Trazodone Hcl | Trazodone Hcl | 123 | 22 |
| Furosemide | Furosemide | 122 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 120 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 111 | 17 |
| Amlodipine Besylate | Amlodipine Besylate | 110 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 108 | 17 |
| Diazepam | Diazepam | 106 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 104 | 20 |
| Clonidine Hcl | Clonidine Hcl | 101 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 98 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 96 | 61 |
| Vraylar | Cariprazine Hcl | 96 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 93 | 13 |
| Lorazepam | Lorazepam | 87 | 16 |
| Losartan Potassium | Losartan Potassium | 84 | 20 |
| Testosterone Cypionate | Testosterone Cypionate | 81 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 12 |
| Sertraline Hcl | Sertraline Hcl | 76 | 13 |
| Aripiprazole | Aripiprazole | 69 | suppressed |
| Estradiol | Estradiol | 64 | 11 |
| Sucralfate | Sucralfate | 64 | suppressed |
| Celecoxib | Celecoxib | 63 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | suppressed |
| Methocarbamol | Methocarbamol | 61 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 61 | 12 |
| Fluconazole | Fluconazole | 60 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | suppressed |
| Famotidine | Famotidine | 56 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 51 | suppressed |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 50 | suppressed |
| Eliquis | Apixaban | 50 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 50 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | suppressed |
| Ozempic | Semaglutide | 49 | 13 |
| Linzess | Linaclotide | 47 | 16 |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 44 | suppressed |
| Niacin Er | Niacin | 43 | suppressed |
| Glimepiride | Glimepiride | 41 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 40 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 40 | 11 |
| Atenolol | Atenolol | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Glyburide | Glyburide | 38 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Lidocaine | Lidocaine | 35 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 24 |
| Vilazodone Hcl | Vilazodone Hcl | 32 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | suppressed |
| Risperidone | Risperidone | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 17 |
| Nitroglycerin | Nitroglycerin | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 28 | 24 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 21 |
| Levofloxacin | Levofloxacin | 27 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Lamotrigine | Lamotrigine | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 24 | suppressed |
| Belsomra | Suvorexant | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Nystatin | Nystatin | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Armodafinil | Armodafinil | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 21 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Novolog | Insulin Aspart | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Aristada | Aripiprazole Lauroxil | 18 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Carvedilol | Carvedilol | 17 | suppressed |
| Erythromycin | Erythromycin Base | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $743.20 · 48 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ARISTADA, Auvelity, CAPLYTA, COBENFY, GVOKE HYPOPEN, LYBALVI, MOUNJARO, NURTEC ODT, REXULTI, VRAYLAR, Veozah, ZAVZPRET, ZTLido | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Aristada play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error